2025-11323Notice

FDA Eases Generic Drug Warnings: Meeting Guidance Drops

Published Date: 6/20/2025

Notice

Summary

The FDA just rolled out new rules for drug makers to meet with them after getting a warning letter about their factories. This helps companies fix problems faster and keeps generic drugs safe and reliable. If you run a generic drug facility, you can now request these meetings starting soon, making the whole process smoother and more transparent—no extra fees involved!

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

Can Request Post‑Warning Meetings

The FDA published final guidance that explains how an eligible generic drug manufacturing facility may request a Post‑Warning Letter Meeting with FDA about its remediation of current good manufacturing practice (CGMP) deficiencies described in a warning letter. This guidance is an implementation of a GDUFA III program enhancement described in the GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027 commitment letter.

How To Prepare Meeting Packages

The guidance describes how to prepare and submit a complete meeting package when requesting a Post‑Warning Letter Meeting. If you run an eligible facility, the document explains the materials and submission process the FDA expects for those meetings.

FDA's Meeting Conduct Process Explained

The guidance explains how the FDA intends to conduct Post‑Warning Letter Meetings with eligible facilities. It lays out FDA's expectations for meeting conduct and interaction related to remediation of CGMP deficiencies.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
6/20/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in